Coronary Artery Disease: Risk Factors, Prevention and 2026 Cholesterol Guidelines
Understand coronary artery disease causes, smoking and metabolic risks, PREVENT risk scoring, LDL, Lp(a), CAC testing, statins and evidence-based prevention.
Understand coronary artery disease causes, smoking and metabolic risks, PREVENT risk scoring, LDL, Lp(a), CAC testing, statins and evidence-based prevention.
Evidence-based guide to heart failure stages A–D, symptoms, ejection fraction, 2026 ESC classification, ARNI, beta-blockers, MRAs, SGLT2 inhibitors and monitoring.
Evidence-based atrial fibrillation guide covering ECG diagnosis, CHA2DS2-VA/CHA2DS2-VASc stroke risk, DOACs, rate and rhythm control, cardioversion and ablation.
Recognize stroke using FAST and BE FAST, know what to do immediately, understand TIA, ischemic versus hemorrhagic stroke, and updated 2026 treatments.
Recognize early heart attack symptoms including chest pressure, breathlessness and atypical presentations; know when to call emergency services and what hospital treatment involves.
Educational pharmacology article. Revised 10 November 2026. Not a substitute for clinical protocols, local labeling or individual assessment. Overview Anticoagulants prevent or treat fibrin-rich thrombosis, including atrial fibrillation–associated embolism and venous thromboembolism. They do not directly dissolve established clots. Choice considers indication, renal/hepatic function, pregnancy, mechanical valves, bleeding risk and drug interactions [1, 2]. Classes…
Updated 10 November 2026. Educational content only; individual clinical care requires current local guidelines and product labeling. Overview Cardiac glycosides and parenteral inotropes increase cardiac contractility through different mechanisms. They are not foundational mortality-reducing treatment for most patients with chronic heart failure with reduced ejection fraction (HFrEF): evidence-based neurohormonal therapies remain essential. Digoxin has selected…
Updated 10 November 2026. Educational content only; individual clinical care requires current local guidelines and product labeling. Overview Hypertension increases the risk of stroke, myocardial infarction, heart failure, kidney disease and premature death. The 2025 AHA/ACC guideline emphasizes repeated accurate blood pressure assessment, lifestyle interventions and individualized drug treatment. Home readings improve monitoring, but confirmation…
Pharmacology education review. Updated 10 November 2026. This is not an individual prescribing protocol; follow current local guidelines and product labeling. Overview Beta-adrenoceptor antagonists reduce catecholamine effects on cardiac rate, contractility, conduction and renin release. Benefits vary by indication and individual agent: beta blockade is not uniformly proven to reduce mortality in every patient with…
Pharmacology education review. Updated 10 November 2026. This is not an individual prescribing protocol; follow current local guidelines and product labeling. Overview Angiotensin-converting enzyme (ACE) inhibitors decrease formation of angiotensin II and increase bradykinin, promoting vasodilation and reducing aldosterone secretion. Indications include hypertension, selected heart-failure regimens, post-MI LV dysfunction and albuminuric CKD. Medication choice should…